




Instance: composition-en-99b35aa72c0e418c8749ea99edf139d2
InstanceOf: CompositionUvEpi
Title: "Composition for vizimpro Package Leaflet"
Description:  "Composition for vizimpro Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa05b3b03b528b8e7156a6b16d80452fc)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vizimpro"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Vizimpro is and what it is used for  </li>
<li>What you need to know before you take Vizimpro </li>
<li>How to take Vizimpro </li>
<li>Possible side effects </li>
<li>How to store Vizimpro </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vizimpro is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vizimpro is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vizimpro contains the active substance dacomitinib, which belongs to a group of medicines called 
protein tyrosine kinase inhibitors which are used to treat cancer. </p>
<p>Vizimpro is used to treat adults with a type of lung cancer called  non-small cell lung cancer . If a test 
has shown that your cancer has certain changes (mutations) in a gene called  EGFR  (epidermal 
growth factor receptor) and has spread to your other lung or other organs, your cancer is likely to 
respond to treatment with Vizimpro. </p>
<p>Vizimpro can be used as your first treatment once your lung cancer has spread to your other lung or 
other organs. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vizimpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vizimpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Vizimpro 
* if you are allergic to dacomitinib or any of the other ingredients of this medicine (listed in 
section 6).  </p>
<p>Warnings and precautions<br />
Talk to your doctor, pharmacist or nurse before taking Vizimpro: 
* if you ever had any other lung problems. Some lung problems may get worse during treatment 
with Vizimpro, as Vizimpro may cause inflammation of the lungs during treatment. 
Symptoms may be similar to those from lung cancer. Tell your doctor right away if you have 
any new or worsening symptoms including difficulty in breathing, shortness of breath, or 
cough with or without phlegm (mucous), or fever. 
* If you are being treated with any of the medicines listed in section Other medicines and 
Vizimpro. </p>
<p>Tell your doctor immediately while taking this medicine: 
* if you develop diarrhoea. Immediate treatment of diarrhoea is important. 
* if you develop skin rash. Early treatment of skin rash is important. 
* if you have any symptoms of a liver problem which may include: yellowing of your skin or 
the white part of your eyes (jaundice), dark or brown (tea coloured) urine, light-coloured 
bowel movements (stools). </p>
<p>Children and adolescents 
Vizimpro has not been studied in children or adolescents and it must not be given to patients under the 
age of 18 years. </p>
<p>Other medicines and Vizimpro 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>In particular, the effects of some medicines may increase when taken with Vizimpro. These include, 
among others: 
* Procainamide, used to treat heart arrhythmias 
* Pimozide and thioridazine, used to treat schizophrenia and psychosis </p>
<p>You should not take these medicines during your treatment with Vizimpro. </p>
<p>The following medicines may reduce how well Vizimpro works: 
* Long-acting medicines for reducing stomach acid, such as proton pump inhibitors (for ulcers, 
indigestion and heartburn). </p>
<p>You should not take these medicines during your treatment with Vizimpro. As an alternative, you can 
take a short-acting medicine, such as an antacid, or an H2 blocker medicine. If you take H2 blocker 
medicine take your dose of Vizimpro at least 2 hours before or 10 hours after taking the H2 blocker 
medicine. </p>
<p>Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>Pregnancy 
You should not become pregnant during treatment with Vizimpro because this medicine could harm 
the baby. If there is any possibility that you may become pregnant you must use effective 
contraception during treatment, and for at least 17 days afterwards. If you become pregnant while 
taking this medicine, you should immediately talk to your doctor. </p>
<p>Breast-feeding 
Do not breast-feed while taking this medicine because it is not known if it can harm your baby. </p>
<p>Driving and using machines 
Tiredness and eye irritation can occur in patients taking Vizimpro. If you feel tired or your eyes are 
irritated, you should use caution when driving or using machines. </p>
<p>Vizimpro contains lactose and sodium 
This medicine contains lactose (found in milk or dairy products). If you have been told by your doctor 
that you have an intolerance to some sugars, contact your doctor before taking this medicine. </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vizimpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vizimpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<ul>
<li>The recommended dose is 45 mg taken by mouth each day. </li>
<li>Take the tablet at about the same time each day. </li>
<li>Swallow the tablet whole with a glass of water. </li>
<li>You can take the tablet with or without meals. </li>
</ul>
<p>Your doctor may decrease the dose of your medicine depending on how well you tolerate it. </p>
<p>If you take more Vizimpro than you should 
If you have taken too much Vizimpro, see a doctor or go to a hospital immediately. </p>
<p>If you forget to take Vizimpro 
If you miss a dose or vomit, take your next dose as scheduled. Do not take a double dose to make up 
for a forgotten tablet. </p>
<p>If you stop taking Vizimpro 
Do not stop taking Vizimpro unless your doctor tells you to. If you have any further questions on the 
use of this medicine, ask your doctor, pharmacist or nurse. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Contact your doctor immediately if you notice any of the following side effects   you may need urgent 
medical treatment: 
  Inflammation of the lungs (common, may affect up to 1 in 10 people) 
Difficulty in breathing, shortness of breath, possibly with a cough or fever. This may mean 
that you have an inflammation of the lungs called interstitial lung disease and can be fatal.<br />
  Diarrhoea (very common, may affect more than 1 in 10 people)<br />
Diarrhoea may lead to fluid loss (common), low blood potassium (very common), and 
worsening kidney function and can be fatal. At first signs of increased frequency of bowel 
movements, contact your doctor immediately, drink plenty of fluids, and start antidiarrhoea 
treatment as soon as possible. You should have an anti-diarrhoeal medicine available before 
you start taking Vizimpro. 
  Skin rash (very common) 
It is important to treat the rash early. Tell your doctor if a rash starts. If treatment for rash is 
not working or the rash is getting worse (for example, you have peeling or cracking of the 
skin) you should tell your doctor immediately, since your doctor may decide to stop your 
treatment with Vizimpro. Rash may occur or worsen in areas exposed to sun. Sun protection 
with protective clothing and sunscreen is recommended. </p>
<p>Tell your doctor as soon as possible if you notice any of the other following side effects: </p>
<p>Very common (may affect more than 1 in 10 people): 
  Inflammation of the mouth and lips 
  Nail problems 
  Dry skin 
  Loss of appetite 
  Dry, red, or itchy eyes 
  Weight loss 
  Hair loss 
  Itching 
  Abnormal liver enzyme blood tests 
  Nausea or vomiting 
  Flushed or painful palms or soles 
  Tiredness 
  Weakness 
  Cracks in the skin </p>
<p>Common (may affect up to 1 in 10 people): 
  Alteration in taste 
  Peeling skin 
  Eyes inflammation 
  Abnormal amount of body hair growth </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vizimpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vizimpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and the blister after EXP. 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>This medicine may pose a risk for the environment. Do not throw away any medicines via wastewater 
or household waste. Ask your pharmacist how to throw away medicines you no longer use. These 
measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Vizimpro contains 
- The active substance is dacomitinib (as dacomitinib monohydrate). Vizimpro film-coated tablets 
come in different strengths. 
Vizimpro 15 mg tablet: each film-coated tablet contains 15 mg dacomitinib 
Vizimpro 30 mg tablet: each film-coated tablet contains 30 mg dacomitinib 
Vizimpro 45 mg tablet: each film-coated tablet contains 45 mg dacomitinib 
- The other ingredients are:<br />
Tablet core: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, 
magnesium stearate (see section 2 Vizimpro contains lactose and sodium). 
Film coating: Opadry II Blue 85F30716 containing polyvinyl alcohol   partially hydrolysed 
(E1203), talc (E553b), titanium dioxide (E171), macrogol (E1521), Indigo carmine aluminium 
lake (E132). </p>
<p>What Vizimpro looks like and contents of the pack 
- Vizimpro 15 mg film-coated tablets are supplied as blue film-coated, round biconvex tablets, 
debossed with  Pfizer  on one side and  DCB15  on the other. </p>
<ul>
<li>
<p>Vizimpro 30 mg film-coated tablets are supplied as blue film-coated, round biconvex tablet, 
debossed with  Pfizer  on one side and  DCB30  on the other. </p>
</li>
<li>
<p>Vizimpro 45 mg film-coated tablets are supplied as blue film-coated, round biconvex tablet, 
debossed with  Pfizer  on one side and  DCB45  on the other. </p>
</li>
</ul>
<p>It is available in blister packs of 30 film-coated tablets (tablets). </p>
<p>Marketing Authorisation Holder 
Pfizer Europe MA EEIG 
Boulevard de la Plaine 1050 Bruxelles 
Belgium </p>
<p>Manufacturer 
Pfizer Manufacturing Deutschland GmbH 
Betriebsst tte Freiburg 
Mooswaldallee 1 
79090 Freiburg 
Germany </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Luxembourg/Luxemburg 
Pfizer NV/SA 
T l/Tel: +32 (0)2 554 62 Lietuva 
Pfizer Luxembourg SARL filialas Lietuvoje 
Tel. + 370 52 51 4<br />
     ,   <br />
 .: +359 2 970 4Magyarorsz g 
Pfizer Kft. 
Tel.: +36-1-488-37- esk  republika 
Pfizer, spol. s r.o. 
Tel.: +420 283 004 Malta 
Vivian Corporation Ltd. 
Tel: + 35621 344Danmark 
Pfizer ApS 
Tlf: +45 44 20 11 Nederland 
Pfizer BV 
Tel: +31 (0)10 406 43 Deutschland 
PFIZER PHARMA GmbH 
Tel: +49 (0)30 550055-51Norge 
Pfizer AS 
Tlf: +47 67 52 61 Eesti 
Pfizer Luxembourg SARL Eesti filiaal<br />
Tel.: +372 666 7 sterreich 
Pfizer Corporation Austria Ges.m.b.H. 
Tel: +43 (0)1 521 15-0 </p>
<p>Pfizer   A.E. 
 .: +30 210 6785 Polska 
Pfizer Polska Sp. z o.o. 
Tel.:+48 22 335 61 Espa a 
Pfizer, S.L. 
Tel: +34 91 490 99 Portugal 
Laborat rios Pfizer, Lda. 
Tel: +351 21 423 5France 
Pfizer<br />
T l: +33 (0)1 58 07 34 Rom nia 
Pfizer Romania S.R.L. 
Tel: +40 (0) 21 207 28 Hrvatska 
Pfizer Croatia d.o.o. 
Tel: +385 1 3908 Slovenija 
Pfizer Luxembourg SARL 
Pfizer, podru nica za svetovanje s podro ja 
farmacevtske dejavnosti, Ljubljana 
Tel.: + 386 (0)1 52 11 Ireland 
Pfizer Healthcare Ireland 
Tel: 1800 633 363 (toll free) 
+44 (0)1304 616Slovensk  republika 
Pfizer Luxembourg SARL, organiza n  zlo ka<br />
Tel.: + 421 2 3355 5 sland 
Icepharma hf. 
S mi: +354 540 8Suomi/Finland 
Pfizer Oy 
Puh./Tel: +358 (0)9 43 00 Italia 
Pfizer S.r.l. 
Tel: +39 06 33 18 Sverige<br />
Pfizer AB 
Tel: +46 (0)8 550 520 K<br />
Pfizer    . . (Cyprus Branch)<br />
 : +357 22 817United Kingdom (Northern Ireland) 
Pfizer Limited 
Tel: +44 (0) 1304 616Latvija 
Pfizer Luxembourg SARL fili le Latvij<br />
Tel.: + 371 670 35 This leaflet was last revised in MM/YYYY </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-99b35aa72c0e418c8749ea99edf139d2
InstanceOf: CompositionUvEpi
Title: "Composition for vizimpro Package Leaflet"
Description:  "Composition for vizimpro Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mpa05b3b03b528b8e7156a6b16d80452fc)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - vizimpro"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Vizimpro
3. Sådan skal du tage Vizimpro
4. Bivirkninger 
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What vizimpro is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What vizimpro is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Vizimpro indeholder det aktive stof dacomitinib, som tilhører en gruppe af lægemidler kaldet
proteintyrosinkinasehæmmere, som bruges til at behandle kræft. 
Vizimpro bruges til behandling af voksne patienter med en type lungekræft, som kaldes "ikke-
småcellet lungekræft". Hvis en test har vist, at du har kræft med ændringer (mutationer) i et gen kaldet 
EGFR (human epidermal vækstfaktorreceptor) og kræften har spredt sig til den anden lunge eller 
andre organer, vil kræften sandsynligvis reagere på behandling med Vizimpro. 
Vizimpro kan bruges som din første behandling, når lungekræften har spredt sig til den anden lunge 
eller andre organer.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take vizimpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take vizimpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Vizimpro

Hvis du er allergisk over for dacomitinib eller et af de øvrige indholdsstoffer i dette 
lægemiddel (angivet i afsnit 6). 
Advarsler og forsigtighedsregler 
Kontakt lægen, apotekspersonalet eller sygeplejersken, før du tager Vizimpro:

Hvis du har andre lungeproblemer. Visse lungeproblemer kan blive værre under behandling 
med Vizimpro, eftersom Vizimpro kan forårsage betændelse i lungerne under behandlingen. 
Symptomerne kan være de samme, som dem der opstår ved lungekræft. Fortæl det straks til 
lægen, hvis du får nye eller forværrede symptomer, herunder åndedrætsbesvær, åndenød eller 
hoste med eller uden slim eller feber. 

Hvis du bliver behandlet med et af de lægemidler, der er anført i afsnittet Brug af anden 
medicin sammen med Vizimpro.
33
Fortæl det straks til lægen, når du tager dette lægemiddel:

Hvis du får diarré. Det er vigtigt, at diarré behandles med det samme. 

Hvis du får hududslæt. Det er vigtigt, at hududslæt behandles med det samme.

Hvis du har symptomer på et leverproblem. Det kan være: gulfarvning af huden eller af det 
hvide i øjnene (gulsot), mørk eller brun (tefarvet) urin, lys afføring.
Børn og unge
Vizimpro er ikke blevet undersøgt hos børn eller unge, og det må ikke gives til patienter under 18 år. 
Brug af andre lægemidler sammen med Vizimpro
Fortæl altid lægen eller apotekspersonalet, hvis du tager andre lægemidler, for nylig har taget andre
lægemidler eller planlægger at tage andre lægemidler.
Virkningen af visse andre lægemidler kan muligvis forstærkes, når de tages sammen med Vizimpro. 
Disse omfatter blandt andet:

Procainamid, som anvendes til at behandle uregelmæssig hjerterytme

Pimozid og thioridazin, som anvendes til behandling af skizofreni og psykose
Du må ikke tage disse lægemidler, mens du behandles med Vizimpro.
De følgende lægemidler kan nedsætte virkningen af Vizimpro:

Langtidsvirkende lægemidler, der nedsætter produktionen af mavesyre såsom 
syrepumpehæmmere (til mavesår, fordøjelsesbesvær og halsbrand).
Du må ikke tage disse lægemidler, mens du behandles med Vizimpro. Som alternativ kan du tage et 
korttidsvirkende lægemiddel, fx syreneutraliserende medicin eller et lægemiddel, der nedsætter 
produktionen af mavesyre, en såkaldt "H2-blokker". Hvis du tager en "H2-blokker", skal du tage din 
Vizimpro-dosis mindst 2 timer før eller 10 timer efter, at du har taget lægemidlet, der blokerer H2. Graviditet og amning
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel.
Graviditet
Du må ikke blive gravid under behandling med Vizimpro, da dette lægemiddel kan skade barnet. Hvis 
der er mulighed for, at du kan blive gravid, skal du anvende sikker prævention under behandlingen, og 
i mindst 17 dage efter behandlingens ophør. Du skal omgående fortælle det til lægen, hvis du bliver 
gravid, mens du tager dette lægemiddel.
Amning
Du må ikke amme, mens du tager dette lægemiddel, eftersom det ikke vides, om denne medicin kan 
skade barnet. 
Trafik- og arbejdssikkerhed
Træthed og øjenirritation kan forekomme hos patienter, som tager Vizimpro. Hvis du føler dig træt, 
eller hvis dine øjne er irriterede, skal du udvise forsigtighed, Når du fører motorkøretøj eller anvender
maskiner.
Vizimpro indeholder lactose og natrium
Dette lægemiddel indeholder lactose (som findes i mælk og mejeriprodukter). Kontakt lægen, før du 
tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke kan tåle visse sukkerarter.
Dette lægemiddel indeholder mindre end 1 mmol natrium (23 mg) pr. tablet, dvs. det er i det
væsentlige natriumfrit.
34</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take vizimpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take vizimpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. 

Den anbefalede dosis er 45 mg dagligt som tages gennem munden. 

Tag tabletten på omtrent samme tid hver dag. 

Slug tabletten hel med et glas vand.

Du kan tage tabletten sammen med eller uden mad. 
Din læge vil måske nedsætte din dosis af lægemidlet afhængigt af, hvor godt du tåler det.
Hvis du har taget for meget Vizimpro
Hvis du har taget for mange Vizimpro tabletter, skal du straks kontakte en læge eller tage på 
hospitalet. 
Hvis du har glemt at tage Vizimpro
Hvis du glemmer en dosis eller kaster op, skal du tage din næste dosis som planlagt. Du må ikke tage 
en dobbeltdosis som erstatning for den glemte tablet.
Hvis du holder op med at tage Vizimpro
Du må ikke stoppe med at tage Vizimpro, medmindre din læge fortæller dig det. Spørg lægen, 
apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Kontakt straks din læge, hvis du får en eller flere af følgende bivirkninger, da du kan have behov for 
akut lægehjælp.
 Lungebetændelse (almindelig, kan forekomme hos op til 1 ud af 10 personer):
Åndedrætsbesvær, åndenød, muligvis med hoste eller feber. Det betyder, at du måske har en 
betændelse i lungerne, der kaldes interstitiel lungesygdom, som kan være dødelig. 
 Diarré (meget almindelig, kan forekomme hos flere end 1 ud af 10 personer): 
Diarré kan føre til væsketab (almindeligt), lavt kaliumindhold i blodet (meget almindeligt) og 
forværret nyrefunktion, og kan være dødelig. Ved de første tegn på øget hyppighed af 
afføring, skal du straks kontakte din læge, du skal drikke masser af væske og starte behandling 
mod diarré så hurtigt som muligt. Du skal have et lægemiddel mod diarré tilgængeligt, inden 
du begynder at tage Vizimpro. 
 Hududslæt (meget almindeligt)
Det er vigtigt, at udslættet behandles tidligt. Fortæl det til lægen, hvis du får begyndende 
udslæt. Hvis behandlingen for udslæt ikke virker, eller udslættet bliver værre (fx hvis huden 
skaller af eller der opstår revner i huden), skal du straks fortælle det til din læge, da din læge 
kan beslutte at stoppe behandlingen med Vizimpro. Udslæt kan opstå eller forværres i 
områder, der udsættes for sol. Beskyt dig mod solen ved hjælp af beskyttende tøj og solcreme.
Kontakt din læge hurtigst muligt, hvis du opdager en eller flere af de følgende bivirkninger:
Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer):
 Betændelse i munden og læberne
 Negleproblemer
 Hudtørhed
 Tab af appetit
 Tørre, røde eller kløende øjne
 Vægttab
35
 Hårtab
 Kløe
 Unormale blodtests af leverenzymer
 Kvalme eller opkastning
 Rødmende eller smertefulde håndflader eller fodsåler
 Træthed
 Svækkelse
 Revner i huden
Almindelig (kan forekomme hos op til 1 ud af 10 personer):
 Smagsforstyrrelser
 Hudafskalning
 Øjenbetændelse
 Unormal hårvækst på kroppen
Indberetning af bivirkninger
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store vizimpro"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store vizimpro"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Tag ikke lægemidlet efter den udløbsdato, der står på pakningen og blisteren efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned.
Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
Dette lægemiddel kan udgøre en risiko for miljøet. Spørg apotekspersonalet, hvordan du skal 
bortskaffe lægemiddelrester. Af hensyn til miljøet må du ikke smide lægemiddelrester i afløbet, 
toilettet eller skraldespanden.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <h2>Vizimpro indeholder:</h2>
<p>Aktivt stof: dacomitinib (som dacomitinibmonohydrat). Vizimpro filmovertrukne tabletter 
findes i forskellige styrker.
Vizimpro 15 mg: hver filmovertrukken tablet indeholder 15 mg dacomitinib
Vizimpro 30 mg: hver filmovertrukken tablet indeholder 30 mg dacomitinib
Vizimpro 45 mg: hver filmovertrukken tablet indeholder 45 mg dacomitinib
-
Øvrige indholdsstoffer: 
Tabletkerne: lactosemonohydrat, mikrokrystallinsk cellulose, natriumstivelsesglykolat, 
magnesiumstearat (se pkt. 2 Vizimpro indeholder laktose og natrium).
Filmovertræk: Opadry II Blue 85F30716 indeholdende polyvinylalkohol - delvist hydrolyseret 
(E1203), talcum (E553b), titandioxid (E171), macrogol (E1521), Indigo carmine aluminium lake 
(E132).
Udseende og pakningsstørrelser
-
Vizimpro 15 mg filmovertrukne tabletter leveres som blå, runde, bikonvekse filmovertrukne 
tabletter, der er præget med “Pfizer" på den ene side og “DCB15" på den anden side.
36
-
Vizimpro 30 mg filmovertrukne tabletter leveres som blå, runde, bikonvekse filmovertrukne 
tabletter, der er præget med “Pfizer" på den ene side og “DCB30" på den anden side.
-
Vizimpro 45 mg filmovertrukne tabletter leveres som blå, runde, bikonvekse filmovertrukne 
tabletter, der er præget med “Pfizer" på den ene side og “DCB45" på den anden side.
Vizimpro findes i blisterpakninger med 30 filmovertrukne tabletter (tabletter).
Indehaver af markedsføringstilladelsen
Pfizer Europe MA EEIG
Boulevard de la Plaine 17
1050 Bruxelles
Belgien
Fremstiller
Pfizer Manufacturing Deutschland GmbH
Betriebsstätte Freiburg
Mooswaldallee 1
79090 Freiburg
Tyskland
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
Luxembourg/Luxemburg
Pfizer NV/SA
Tél/Tel: +32 (0)2 554 62 11
Lietuva
Pfizer Luxembourg SARL filialas Lietuvoje
Tel. + 370 52 51 4000
България
Пфайзер Люксембург САРЛ, Клон България
Тел.: +359 2 970 4333
Magyarország
Pfizer Kft.
Tel.: +36-1-488-37-00
Česká republika
Pfizer, spol. s-r.o.
Tel.: +420 283 004 111
Malta
Vivian Corporation Ltd.
Tel: + 35621 344610
Danmark
Pfizer ApS
Tlf: +45 44 20 11 00
Nederland
Pfizer BV
Tel: +31 (0)10 406 43 01
Deutschland
PFIZER PHARMA
Tel: +49 (0)30 550055-51000
Norge
Pfizer AS
Tlf: +47 67 52 61 00
Eesti
Pfizer Luxembourg SARL Eesti filiaal 
Tel.: +372 666 7500
Österreich
Pfizer Corporation Austria Ges.m.b.H.
Tel: +43 (0)1 521 15-0
Ελλάδα
Pfizer Ελλάς A.E.
Τηλ.: +30 210 6785 800
Polska
Pfizer Polska Sp. z o.o.
Tel.:+48 22 335 61 00
España
Pfizer S.L.
Tél: +34 91 490 99 00
Portugal
Laboratórios Pfizer, Lda.
Tel: +351 21 423 5500
37
France
Pfizer 
Tel: +33 (0)1 58 07 34 40
România
Pfizer Romania S.R.L.
Tel: +40 (0) 21 207 28 00
Hrvatska
Pfizer Croatia d.o.o.
Tel: +385 1 3908 777
Slovenija
Pfizer Luxembourg SARL
Pfizer, podružnica za svetovanje s področja 
farmacevtske dejavnosti, Ljubljana
Tel.: + 386 (0)1 52 11 400
Ireland
Pfizer Healthcare Ireland
Tel: 1800 633 363 (toll free)
+44 (0)1304 616161
Slovenská republika
Pfizer Luxembourg SARL, organizačná zložka 
Tel.: + 421 2 3355 5500
Ísland
Icepharma hf.
Sími: +354 540 8000
Suomi/Finland
Pfizer Oy
Puh./Tel: +358 (0)9 43 00 40
Italia
Pfizer S.r.l.
Tel: +39 06 33 18 21
Sverige 
Pfizer AB
Tel: +46 (0)8 550 520 00
Kύπρος
Pfizer Ελλάς Α.Ε. (Cyprus Branch) 
Τηλ: +357 22 817690
United Kingdom (Northern Ireland)
Pfizer Limited
Tel: +44 (0) 1304 616161
Latvija
Pfizer Luxembourg SARL filiāle Latvijā
Tel.: + 371 670 35 775
Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ}.
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu.</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-99b35aa72c0e418c8749ea99edf139d2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vizimpro Package Leaflet for language en"
Description: "ePI document Bundle for vizimpro Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-99b35aa72c0e418c8749ea99edf139d2"
* entry[0].resource = composition-en-99b35aa72c0e418c8749ea99edf139d2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp99b35aa72c0e418c8749ea99edf139d2"
* entry[=].resource = mp99b35aa72c0e418c8749ea99edf139d2
                            
                    
Instance: bundlepackageleaflet-da-99b35aa72c0e418c8749ea99edf139d2
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for vizimpro Package Leaflet for language da"
Description: "ePI document Bundle for vizimpro Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-99b35aa72c0e418c8749ea99edf139d2"
* entry[0].resource = composition-da-99b35aa72c0e418c8749ea99edf139d2

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp99b35aa72c0e418c8749ea99edf139d2"
* entry[=].resource = mp99b35aa72c0e418c8749ea99edf139d2
                            
                    



Instance: mp99b35aa72c0e418c8749ea99edf139d2
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Vizimpro 15 mg film-coated tablets"
Description: "Vizimpro 15 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/19/1354/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Vizimpro 15 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 99b35aa72c0e418c8749ea99edf139d2ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "vizimpro"

* status = #current
* mode = #working

* title = "List of all ePIs associated with vizimpro"

* subject = Reference(mpa05b3b03b528b8e7156a6b16d80452fc)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#vizimpro "vizimpro"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-99b35aa72c0e418c8749ea99edf139d2) // vizimpro en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-99b35aa72c0e418c8749ea99edf139d2) // vizimpro da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-99b35aa72c0e418c8749ea99edf139d2
InstanceOf: List

* insert 99b35aa72c0e418c8749ea99edf139d2ListRuleset
    